Skip to main content

Astrocytoma Clinical Trials

Review the astrocytoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 36

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Status: Active
Location: 118 locations
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Status: Active
Location: 39 locations
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Status: Active
Location: 26 locations
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Status: Active
Location: 17 locations
Adjuvant 177Lu-PSMA-617 Radiopharmaceutical Therapy with Temozolomide for the Treatment of IDH Wild Type Gliomas Expressing PSMA following Standard Treatment
Status: Active
Location: 7 locations
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Status: Active
Location: 6 locations
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Status: Active
Location: 5 locations
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Status: Active
Location: 6 locations
rQNestin34.5v.2 with or without Cyclophosphamide in Treating Patients with Recurrent Malignant Glioma
Status: Active
Location: 4 locations
DB107-RRV in Combination with DB107-FC for the Treatment of Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Status: Active
Location: 3 locations
Ex Vivo Expanded CD34+ Hematopoietic Stem Cells in Combination with Nivolumab for the Treatment of Recurrent, Progressive, or Refractory Pediatric High-grade Glioma
Status: Active
Location: 3 locations
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases
Status: Active
Location: 3 locations
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Location: 2 locations
A Vaccine (RNA-LP) for the Treatment of Recurrent Pediatric High-Grade Glioma and Recurrent Osteosarcoma, RNA PRIME Trial
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
Hippocampal-Avoidance Using Intensity-Modulated Radiation Therapy for the Treatment of Low-Grade Glioma
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Study of Olutasidenib and Temozolomide in HGG
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tretinoin and Retifanlimab in Treating Patients with Recurrent IDH-Mutant Glioma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Pembrolizumab and M032 (NSC 733972) in Treating Patients with Newly Diagnosed or Recurrent/Progressive Glioblastoma, Anaplastic Astrocytoma, or Gliosarcoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Mirdametinib for the Treatment of Low-Grade Glioma
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Re-Administration of C134 for the Treatment of Recurrent Malignant Gliomas in Patients Previously Treated with C134
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Grade 4 Recurrent Astrocytoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas